Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

The rodent thyroid C-cell signal and its human relevance — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-021/5
Series
Evidence synthesis
Version
1.3
Published
23 Feb 2024
Last reviewed
23 Aug 2024
Next review
23 Feb 2026
Identifier
10.71829/cei.syn.21
Certainty
Low
Cycle
2024 Q1
Review type
Safety review
Search executed
16 Jan 2024

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
24 Nov 20230.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
16 Jul 20241.1Comment-period disposition appliedAmendments arising from the disposition of a public comment period were applied. Each amendment is traceable to a numbered submission.
08 Nov 20241.2Analysis method changedThe pooling method was changed from a fixed-effect to a random-effects model following observation of between-study heterogeneity exceeding the pre-specified threshold.
25 May 20251.3Certainty rating revisedThe certainty rating for one outcome was revised following the addition of a contributing study. The rationale is recorded in the certainty assessment section.
25 Jan 20261.0Certainty rating revisedThe certainty rating for one outcome was revised following the addition of a contributing study. The rationale is recorded in the certainty assessment section.
21 Jun 20261.1Search re-runThe search was re-run to the current cycle date. Newly identified records were screened against the registered criteria without modification of those criteria.
Current version 1.3, ratified in the 2024 Q1 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
ESSENCE05 Dec 2023No response
EXENATIDE-GE-PD05 Jan 2024No response
STRIDE17 Nov 2023Supplied on request
FLOW17 Dec 2023Partially supplied
STEP-HFpEF-DM12 Nov 2023Refused
SELECT29 Nov 2023Refused
STEP-HFpEF02 Dec 2023Refused
STEP-530 Nov 2023Refused

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.